<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896854</url>
  </required_header>
  <id_info>
    <org_study_id>UnicarTherapy20190308</org_study_id>
    <nct_id>NCT03896854</nct_id>
  </id_info>
  <brief_title>CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Pilot Study of the Efficacy and Safety of CD19 Targeted Chimeric Antigen Receptor Engineered T Cell in the Treatment of Relapsed or Refractory CD19 Positive Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of
      targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the
      treatment of CD19 positive relapsed or refractory acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will receive infusion of CART cells targeting CD19 to confirm the safety and
      efficacy of CD19 CART Cells in relapsed or refractory acute myeloid leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events are evaluated with CTCAE V4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19 positive relapsed or refractory acute myeloid leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART-19</intervention_name>
    <description>CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19 cells/kg).</description>
    <arm_group_label>CD19 positive relapsed or refractory acute myeloid leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with CD19+ relapsed/refractory acute myeloid leukemia

          -  Age 6-65 years.

          -  Left ventricular ejection fractions≥ 0.5 by echocardiography.

          -  Creatinine &lt; 1.6 mg/dL.

          -  Aspartate aminotransferase/aspartate aminotransferase &lt; 3x upper limit of normal.

          -  Bilirubin &lt;2.0 mg/dL.

          -  Karnofsky performance status ≥ 60

          -  Expected survival time ≥ 3 months (according to investigator's judgement)

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Uncontrolled active infection.

          -  Active hepatitis B or hepatitis C infection.

          -  Class III/IV cardiovascular disability according to the New York Heart Association
             Classification.

          -  HIV infection.

          -  Patients with history of seizure

          -  Active central nervous system leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowen Tang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowen Tang, Ph.D.</last_name>
    <phone>(0086)51267781856</phone>
    <email>tangxiaowen@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Yu, Ph.D.</last_name>
    <phone>(0086)13818629089</phone>
    <email>ylyh188@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Tang, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

